The company
mbiomics develops microbiome analysis technology to inform targeted therapies.
The funding
mbiomics, based in Munich, Germany, announced €12M in Series A financing on April 30, 2026.
Participants include MIG Fonds, Bayern Kapital.
mbiomics Raises €12M Series A
mbiomics raised €12M in a Series A round announced on April 30, 2026. mbiomics develops microbiome analysis technology to inform targeted therapies.
Round size
€12MStage
Series AHeadquarters
GermanyAnnounced
Apr 30, 202603 / Related rounds
Related funding rounds
Series C+ · Healthtech
Storm Therapeutics
A biotechnology company developing small molecule drugs that target RNA modifying enzymes for the treatment of cancer.
Series A · Deeptech
Subra
Subra is a Danish deep-tech developing revolutionary superconductor solutions for zero-loss power transmission and fusion energy.
Series A · Space
Atmos Space Cargo
Germany-based startup developing and manufacturing technology for space.